CN Patent

CN116444377A — 一种氧化氮供体型曲前列尼尔类衍生物及其药物组合物和用途

Assigned to Guangzhou Kaishi Pharmaceutical Co ltd · Expires 2023-07-18 · 3y expired

What this patent protects

本发明公开了曲前列尼尔偶联一氧化氮(NO)供体药物，如下式Ⅰ所示，本发明涉及曲前列尼尔偶联NO供体药物、其药物组合物及用途，本发明所述的曲前列尼尔偶联NO供体药物，解决了曲前列尼尔疗效较弱及NO给药不便剂量无法控制等缺陷，并通过两者协同作用提高了药物的有效性和患者的依从性，同时药物有效性控制也得到了提高。

USPTO Abstract

本发明公开了曲前列尼尔偶联一氧化氮(NO)供体药物，如下式Ⅰ所示，本发明涉及曲前列尼尔偶联NO供体药物、其药物组合物及用途，本发明所述的曲前列尼尔偶联NO供体药物，解决了曲前列尼尔疗效较弱及NO给药不便剂量无法控制等缺陷，并通过两者协同作用提高了药物的有效性和患者的依从性，同时药物有效性控制也得到了提高。

Drugs covered by this patent

Patent Metadata

Patent number
CN116444377A
Jurisdiction
CN
Classification
—
Expires
2023-07-18
Drug substance claim
No
Drug product claim
No
Assignee
Guangzhou Kaishi Pharmaceutical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.